Tamás Zelei1, Nicholas D Mendola2, Baher Elezbawy3, Bertalan Németh4, Jonathan D Campbell2. 1. Syreon Research Institute, Mexikói str. 65/A, Budapest, 1142, Hungary. tamas.zelei@syreon.eu. 2. Center for Pharmaceutical Outcomes Research, University of Colorado, Aurora, CO, USA. 3. Syreon Middle East, Alexandria, Egypt. 4. Syreon Research Institute, Mexikói str. 65/A, Budapest, 1142, Hungary.
Abstract
BACKGROUND: Traditionally, the economic value of health technologies is assessed with cost-effectiveness (CE) and budget impact (BI) analyses. However, the evaluation of rare disease therapies often considers novel value criteria. Multi-criteria decision analysis (MCDA) is a promising tool in the assessment of value criteria that typically cannot be captured with traditional approaches. OBJECTIVES: The objective of this research was to investigate the criteria and scoring functions applied in value frameworks and MCDA tools relevant to the evaluation of rare disease therapies. The aim was to gain a better understanding of the domains and measurement of commonly referenced novel value criteria. METHODS: A systematic literature review was performed covering the period from 2013 to 2019. MCDA or value framework articles and structured review papers on orphan-drug-specific MCDA articles were reviewed. Information sources included MEDLINE, Embase, Scopus, and 26 other gray literature sources. A descriptive review of identified criteria and scoring functions was performed, with special focus on "novel" value criteria that are traditionally not considered in CE or BI analyses. RESULTS: In total, 15 relevant value frameworks and MCDA tools were identified. These studies included a large number (n = 56) of individual value criteria. The most commonly included novel criteria were unmet medical need, severity of disease, and reduction in uncertainty. The identified scoring functions (measurement methods) for novel criteria were highly heterogeneous and tailored. Standardized scoring functions were not observed. Additionally, the studies did not provide their rationale for choosing a specific scoring function for a criterion. CONCLUSIONS: MCDA is a promising tool to include novel value criteria into the health technology assessment of therapies for rare diseases. To support the development of a transparent and justified evaluation process, scoring functions should be further investigated.
BACKGROUND: Traditionally, the economic value of health technologies is assessed with cost-effectiveness (CE) and budget impact (BI) analyses. However, the evaluation of rare disease therapies often considers novel value criteria. Multi-criteria decision analysis (MCDA) is a promising tool in the assessment of value criteria that typically cannot be captured with traditional approaches. OBJECTIVES: The objective of this research was to investigate the criteria and scoring functions applied in value frameworks and MCDA tools relevant to the evaluation of rare disease therapies. The aim was to gain a better understanding of the domains and measurement of commonly referenced novel value criteria. METHODS: A systematic literature review was performed covering the period from 2013 to 2019. MCDA or value framework articles and structured review papers on orphan-drug-specific MCDA articles were reviewed. Information sources included MEDLINE, Embase, Scopus, and 26 other gray literature sources. A descriptive review of identified criteria and scoring functions was performed, with special focus on "novel" value criteria that are traditionally not considered in CE or BI analyses. RESULTS: In total, 15 relevant value frameworks and MCDA tools were identified. These studies included a large number (n = 56) of individual value criteria. The most commonly included novel criteria were unmet medical need, severity of disease, and reduction in uncertainty. The identified scoring functions (measurement methods) for novel criteria were highly heterogeneous and tailored. Standardized scoring functions were not observed. Additionally, the studies did not provide their rationale for choosing a specific scoring function for a criterion. CONCLUSIONS: MCDA is a promising tool to include novel value criteria into the health technology assessment of therapies for rare diseases. To support the development of a transparent and justified evaluation process, scoring functions should be further investigated.
Authors: Darius N Lakdawalla; Jalpa A Doshi; Louis P Garrison; Charles E Phelps; Anirban Basu; Patricia M Danzon Journal: Value Health Date: 2018-02 Impact factor: 5.725
Authors: Michael F Drummond; David A Wilson; Panos Kanavos; Peter Ubel; Joan Rovira Journal: Int J Technol Assess Health Care Date: 2007 Impact factor: 2.188
Authors: Praveen Thokala; Nancy Devlin; Kevin Marsh; Rob Baltussen; Meindert Boysen; Zoltan Kalo; Thomas Longrenn; Filip Mussen; Stuart Peacock; John Watkins; Maarten Ijzerman Journal: Value Health Date: 2016-01-08 Impact factor: 5.725
Authors: Gillian D Sanders; Peter J Neumann; Anirban Basu; Dan W Brock; David Feeny; Murray Krahn; Karen M Kuntz; David O Meltzer; Douglas K Owens; Lisa A Prosser; Joshua A Salomon; Mark J Sculpher; Thomas A Trikalinos; Louise B Russell; Joanna E Siegel; Theodore G Ganiats Journal: JAMA Date: 2016-09-13 Impact factor: 56.272